Sedana Medical submits market approval application for the drug Sedaconda
STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for market approval for the drug candidate Sedaconda (isoflurane), formerly known as IsoConDa, for inhaled sedation in intensive care. The applica...
2020-11-27 20:35
2863
Positive Interim Analysis in Pivotal IsoConDa Phase III Study
STOCKHOLM, March 8, 2019 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the results of the interim analysis for the company's pivotal phase III study aimed at getting the candidate drug IsoConDa (isoflurane) approved for inhalation sedation in intensive care inEur...
2019-03-08 15:33
1750
